XOMA price target raised to $6 from $5 at Ladenburg

theflyonthewall.com

Ladenburg raised its price target on XOMA after the company reported top-line Phase II data for its Behcet's Uveitis treatment, Gevokizumab, that the firm views as positive. Ladenbirg thinks the data further derisks the upcoming EYEGUARD-A trial and it reiterates a Buy rating on XOMA.

Rates

View Comments (0)